Clinical Trials
10 trialsNCT05322330 2026-06-02
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT03992339 2025-02-07
SEARCH
Antengene Corporation
Phase 2 Completed
NCT06212596 2024-01-19
MUKtwelve
University of Leeds
Phase 2 Completed
NCT03944057 2023-06-15
MARCH
Antengene Corporation
Phase 2 Completed
NCT02025985 2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02088541 2023-01-26
SOPRA
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02336815 2023-01-26
STORM
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02249091 2021-08-25
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
GSO Global Clinical Research BV
Phase 2 Completed
NCT02402764 2020-09-11
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02250885 2019-09-17
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Gabrail Cancer Center Research
Phase 2 Completed